Nitec Pharma Licenses Tarenflurbil for Chronic Inflammation and Pain

Nitec Pharma AG, an emerging specialty pharma company, announces the signing of an agreement with PAZ GmbH for the exclusive worldwide rights to Tarenflurbil, PAZ’s anti-inflammatory drug, for the treatment of chronic inflammation and pain.
Business Wire